Agios Pharmaceuticals Inc
AGIOHealthcare|Biotechnology|USA
$41.23
-1.56 (-3.65%)
Tangible Book
$40.97
Financials
Financial Snapshot
Market Cap
$2.45B
Enterprise Value
$77.9M
Revenue (TTM)
$66.0M
Net Income (TTM)
$-422.6M
Cash & Equivalents
—
Net Cash/Share
$0.64
Free Cash Flow (TTM)
$-394.7M
Operating CF (TTM)
$-380.4M
Debt/Equity
0.02
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$95.1M
Monthly Burn
$31.7M
Est. Runway
—
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $541.3M | $423.9M | $585.3M | $564.9M | $572.9M | $1.02B | $783.1M | $776.9M | $893.7M | $854.4M | $113.6M | |
| Operating Cash Flow | $38.6M | $-285.2M | $-304.4M | $-370.6M | $-290.8M | $-407.3M | $-309.5M | $-296.1M | $-389.8M | $-373.0M | $-380.4M | |
| Free Cash Flow | $28.6M | $-289.9M | $-311.4M | $-382.6M | $-304.9M | $-413.1M | $-314.4M | $-314.6M | $-391.5M | $-387.3M | $-394.7M | |
| Capital Expenditure | $-9.9M | $-4.6M | $-7.0M | $-12.0M | $-14.1M | $-5.7M | $-4.9M | $-18.5M | $-1.7M | $-14.3M | $-14.3M | |
| Financing Cash Flow | $169.8M | $285.1M | $546.0M | $289.6M | $261.5M | $-765.8M | $2.4M | $5.4M | $14.4M | $8.7M | $9.1M |
R&D Spending
R&D (TTM)
$347.9M
R&D Intensity
526.8%
R&D Growth YoY
+2.5%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $69.9M | $43.0M | $94.4M | $0.00 | $0.00 | $0.00 | $14.2M | $26.8M | $36.5M | $54.0M | $66.0M | |
| R&D Expense | $220.2M | $292.7M | $341.3M | $214.3M | $220.8M | $257.0M | $279.9M | $295.5M | $301.3M | $339.5M | $347.9M | |
| R&D % of Revenue | 315.0% | 680.5% | 361.6% | — | — | — | 1965.7% | 1101.8% | 825.5% | 628.4% | 526.8% | |
| SG&A | $50.7M | $71.1M | $114.1M | $102.0M | $115.1M | $121.4M | $121.7M | $119.9M | $156.8M | $180.3M | $187.1M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $69.9M | $43.0M | $94.4M | $0.00 | $0.00 | $0.00 | $14.2M | $26.8M | $36.5M | $54.0M | $66.0M | |
| Cost of Goods Sold | $0.00 | $0.00 | $1.4M | $-116.6M | $-200.4M | $0.00 | $1.7M | $2.9M | $4.2M | $6.3M | $6.6M | |
| Gross Profit | $69.9M | $43.0M | $93.0M | $116.6M | $200.4M | $0.00 | $12.5M | $23.9M | $32.3M | $47.7M | $59.5M | |
| R&D | $220.2M | $292.7M | $341.3M | $214.3M | $220.8M | $257.0M | $279.9M | $295.5M | $301.3M | $339.5M | $347.9M | |
| SG&A | $50.7M | $71.1M | $114.1M | $102.0M | $115.1M | $121.4M | $121.7M | $119.9M | $156.8M | $180.3M | $187.1M | |
| Operating Income | $-201.0M | $-320.8M | $-362.5M | $-316.3M | $-335.9M | $-378.4M | $-389.0M | $-391.5M | $-425.7M | $-472.1M | $-475.5M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $-17.8M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $-198.5M | $-314.7M | $-346.0M | $-301.4M | $-329.3M | $-356.5M | $-231.8M | $-352.1M | $718.0M | $-413.8M | $-423.6M | |
| Net Income | $-198.5M | $-314.7M | $-346.0M | $-411.5M | $-327.4M | $1.60B | $-231.8M | $-352.1M | $673.7M | $-412.8M | $-422.6M | |
| EPS (Diluted) | -5.07 | -6.75 | -6.03 | -6.86 | -4.74 | 26.55 | -4.23 | -6.33 | 11.64 | -7.12 | -7.25 | |
| EBITDA | $-195.3M | $-314.4M | $-338.9M | $-308.2M | $-326.1M | $-369.2M | $-380.5M | $-384.9M | $-420.1M | $-467.0M | $-470.3M | |
| Shares Out. (M) | 39.13 | 46.59 | 57.42 | 59.99 | 69.00 | 60.45 | 54.79 | 55.65 | 57.89 | 57.97 | 58.78 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $160.8M | $102.7M | $70.5M | $80.9M | $127.4M | $203.1M | $139.3M | $88.2M | $76.2M | $89.1M | $113.6M | |
| Marketable Securities | $380.6M | $321.2M | $514.8M | $483.9M | $445.5M | $816.9M | $643.9M | $688.7M | $817.5M | $765.3M | $0.00 | |
| Total Current Assets | $559.9M | $445.3M | $613.8M | $611.7M | $636.7M | $1.06B | $832.8M | $833.8M | $965.6M | $942.1M | $834.8M | |
| Total Assets | $619.1M | $614.4M | $858.5M | $890.7M | $853.0M | $1.44B | $1.24B | $937.1M | $1.66B | $1.30B | $1.18B | |
| Total Current Liabilities | $88.4M | $94.9M | $93.5M | $92.9M | $94.4M | $59.8M | $62.6M | $68.0M | $81.2M | $82.2M | $58.8M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $260.5M | $238.9M | $170.9M | $250.2M | $453.5M | $145.8M | $137.9M | $126.1M | $122.2M | $104.1M | $75.9M | |
| Stockholders' Equity | $358.6M | $375.5M | $687.5M | $640.5M | $399.5M | $1.29B | $1.10B | $811.0M | $1.54B | $1.19B | $2.43B | |
| Retained Earnings | $-483.2M | $-798.1M | $-1.10B | $-1.52B | $-1.84B | $-238.8M | $-470.6M | $-822.6M | $-148.9M | $-561.7M | $-802.5M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $38.6M | $-285.2M | $-304.4M | $-370.6M | $-290.8M | $-407.3M | $-309.5M | $-296.1M | $-389.8M | $-373.0M | $-380.4M | |
| Capital Expenditure | $-9.9M | $-4.6M | $-7.0M | $-12.0M | $-14.1M | $-5.7M | $-4.9M | $-18.5M | $-1.7M | $-14.3M | $-14.3M | |
| Free Cash Flow | $28.6M | $-289.9M | $-311.4M | $-382.6M | $-304.9M | $-413.1M | $-314.4M | $-314.6M | $-391.5M | $-387.3M | $-394.7M | |
| Investing Cash Flow | $-119.3M | $-57.9M | $-273.8M | $91.4M | $75.7M | $1.25B | $243.3M | $239.6M | $363.4M | $377.2M | $405.9M | |
| Financing Cash Flow | $169.8M | $285.1M | $546.0M | $289.6M | $261.5M | $-765.8M | $2.4M | $5.4M | $14.4M | $8.7M | $9.1M | |
| Issuance of Stock | $162.2M | $270.3M | $516.2M | $277.2M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-802.5M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $0.00 | $0.00 | $0.00 | $-113.0K | $-336.0K | $-578.0K | $-331.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $42.1M | $47.8M | $73.4M | $58.0M | $61.6M | $53.5M | $49.3M | $44.8M | $42.8M | $52.6M | $56.7M | |
| Net Change in Cash | $89.0M | $-58.0M | $-32.2M | $10.4M | $46.5M | $75.7M | $-63.9M | $-51.1M | $-12.0M | $12.9M | $34.6M |
Dilution Tracker
Shares Outstanding
59M
5-Year Share Growth
-2.8%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 39.13 | 46.59 | 57.42 | 59.99 | 69.00 | 60.45 | 54.79 | 55.65 | 57.89 | 57.97 | 58.78 | |
| YoY Change % | — | 19.1% | 23.2% | 4.5% | 15.0% | -12.4% | -9.4% | 1.6% | 4.0% | 0.1% | 1.4% | |
| Stock Issuance | $162.2M | $270.3M | $516.2M | $277.2M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-802.5M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $42.1M | $47.8M | $73.4M | $58.0M | $61.6M | $53.5M | $49.3M | $44.8M | $42.8M | $52.6M | $56.7M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 98.5% | 0.0% | 0.0% | 0.0% | 88.0% | 89.3% | 88.6% | 88.3% | 90.0% | |
| Operating Margin % | -287.6% | -745.8% | -384.0% | 0.0% | 0.0% | 0.0% | -2732.1% | -1459.5% | -1166.5% | -873.9% | -720.0% | |
| Net Margin % | -284.0% | -731.6% | -366.6% | 0.0% | 0.0% | 0.0% | -1627.8% | -1312.6% | 1845.9% | -764.0% | -639.8% | |
| EBITDA Margin % | -279.4% | -730.9% | -359.0% | 0.0% | 0.0% | 0.0% | -2671.9% | -1434.8% | -1151.0% | -864.3% | -712.0% | |
| FCF Margin % | 41.0% | -673.9% | -329.9% | 0.0% | 0.0% | 0.0% | -2207.6% | -1172.7% | -1072.7% | -716.8% | -597.6% | |
| ROE % | -56.4% | -85.7% | -65.1% | -62.0% | -63.0% | 189.7% | -19.4% | -36.8% | 57.3% | -30.2% | -27.3% | |
| ROA % | -38.2% | -51.0% | -47.0% | -47.0% | -37.5% | 140.1% | -17.3% | -32.4% | 51.8% | -27.9% | -30.6% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / 3.12 / 5.43
Industry Med.27.51
P/S36.42
Historical16.96 / 52.70 / 2008.00
Industry Med.9.49
P/B1.01
Historical0.62 / 4.50 / 10.92
Industry Med.2.93
EV/EBITDA-5.01
Historical-14.81 / -6.25 / -0.40
Industry Med.13.02
EV/Revenue35.66
Historical-105.99 / 30.64 / 99999999.99
Industry Med.8.59
P/FCF—
Historical19.15 / 38.52 / 60.67
Industry Med.27.13
Intrinsic Value Models
Tangible Book
$40.97
Net Current Assets
$12.790
Net-Net Working Capital
$1.14
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | At Loss | At Loss | At Loss | At Loss | At Loss | 1.24 | At Loss | At Loss | 2.82 | At Loss | At Loss | |
| PS Ratio | 23.37 | 61.94 | 28.05 | - | - | - | 108.00 | 46.20 | 52.16 | 29.21 | 36.42 | |
| PB Ratio | 4.91 | 7.43 | 3.90 | 5.10 | 7.52 | 1.38 | 1.40 | 1.54 | 1.22 | 1.33 | 1.01 | |
| EV/EBITDA | -6.25 | -7.53 | -6.19 | -9.13 | -7.77 | -2.34 | -2.23 | -1.41 | -2.48 | -1.66 | -5.01 | |
| EV/Revenue | 17.46 | 55.04 | 22.24 | 0.00 | 0.00 | 0.00 | 59.56 | 20.17 | 28.53 | 14.38 | 35.66 |
Analyst Estimates & Quality
Altman Z-Score
18.10
Safe
Piotroski F-Score
3
Weak
Beneish M-Score
-0.54
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $118.08M | $258.33M | $392.36M |
| Net Income | $-372.93M | $-291.69M | $-212.75M |
| EPS | -6.25 | -4.69 | -3.62 |
| Book Value per Share | 14.16 | 10.15 | 7.13 |
| Operating Cash Flow per Share | -5.66 | -4.87 | -3.19 |
| Operating CF | $-332.41M | $-286.27M | $-187.52M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Product revenue, net | $54.0M |
By Geography
| Segment | 2025 |
|---|---|
| Product revenue, net - U.S. | $49.2M |
| Product revenue, net - Rest of world | $4.9M |